NWPHARMATECH
is a Clinical Stage Biotech Company with a Focus on Psychiatric & Neurological Disorders
NWPharmaTech’s expert team combines academic research, cutting-edge technology and clinical development to bring to market new drug formulations targeting mental health conditions.
These therapeutic interventions will support a return to homeostasis, empowering patients to lead longer and healthier lives.
Initial Target Indications – Psychiatric and Neurological Disorders
We are advancing to Phase IIB trials in our lead indicaiton of Clinical High Risk for Psychosis, as well as Phase IIA/B trials elsewhere within the CNS space.
Our Work
Patented Drug Formulation Platform
A new generation of drug delivery technologyOur patented drug delivery technology unlocks superior bioavailability and thus better therapeutic potential and lower COGS.
Target Diseases in Clinical Development
Our Drug PipelineWe are advancing to Phase IIB trials in our lead indicaiton of Clinical High Risk for Psychosis, as well as Phase IIA/B trials elsewhere within the CNS space.
OUR TEAM
We are a driven team of specialists, committed to advancing research in Psychiatric and Neurological Disorders. Our team has experience across multiple sectors – pharmaceutical operations, research and development, intellectual property, marketing and finance – and is based in the UK, Europe and North America.